CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Adolescents and young adults are increasingly using GLP-1 receptor agonists for weight management, raising concerns among ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Clinics, ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

Discover a recent report that states that, although GLP-1 medicines are generally well tolerated, there have been cases of ...

There are two ways in which industry can respond to the GLP-1 craze. On the one hand, they can, like Nestlé, create smaller ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Josephs joins forces with LifeRx.md to redefine health through doctor-led GLP‑1 wellness programs—merging celeb credibility ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.